Alberta Investment Management Corp Buys Shares of 68,300 Edwards Lifesciences Corporation $EW

Alberta Investment Management Corp purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 68,300 shares of the medical research company’s stock, valued at approximately $5,312,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EW. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after acquiring an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Atlantic Union Bankshares Corp lifted its holdings in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after purchasing an additional 11,384 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new position in shares of Edwards Lifesciences in the second quarter worth approximately $300,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. BTIG Research restated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, November 3rd. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Wells Fargo & Company increased their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 43,804 shares of company stock worth $3,699,082. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $78.97 on Thursday. The business’s 50-day moving average is $82.97 and its 200 day moving average is $81.04. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a market capitalization of $45.82 billion, a P/E ratio of 43.15, a P/E/G ratio of 2.08 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.